MERC stock news

MERC stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.

See the full wire

20 wire items

2026-10-29 18:10:14 UTC#539739newconfirmednews

Merck projects 2026 revenue of $66.8B-$67.3B and EPS of $2.77-$2.82 as it invests ahead of Keytruda patent cliff

seeking alphaimportance 0.60trust 0.70Merck & Co., Inc. +0.20Keytruda -0.20

2026-10-29 14:35:00 UTC#538240duplicateconfirmednews

Merck Q3 revenue and profit beat estimates, full-year guidance raised on Keytruda and Winrevair strength

dow_jonesimportance 0.30trust 0.90Merck & Co., Inc. +0.60Robert Davis +0.40Keytruda +0.50+1 entities

2026-10-29 14:24:00 UTC#538169updateconfirmednews

Merck CEO Davis expresses confidence in long-term growth outlook beyond 2028 Keytruda patent expiration

dow_jonesimportance 0.50trust 0.80Merck & Co., Inc. +0.30Robert Davis +0.30Keytruda +0.20

2026-10-29 13:35:56 UTC#537749duplicateconfirmednews

Eli Lilly and Merck report Q3 results exceeding Wall Street estimates

yahooimportance 0.30trust 0.60Eli Lilly and Company +0.50Merck & Co., Inc. +0.50

2026-10-29 12:59:21 UTC#537538newconfirmednews

Merck & Co. Q3 2026 earnings call begins

tradingviewimportance 0.40trust 0.70Merck & Co., Inc. 0

2026-10-29 12:47:00 UTC#537356duplicateconfirmedanalysis

Merck Q3 earnings beat estimates with $2.49 EPS, but investor focus remains on post-2028 pipeline

dow_jonesimportance 0.30trust 0.80Merck & Co., Inc. +0.40Keytruda +0.50

2026-10-29 11:21:56 UTC#536710duplicateconfirmednews

Merck shares rise following Q3 earnings beat and raised 2026 profit outlook

yahooimportance 0.30trust 0.60Merck & Co., Inc. +0.60Keytruda +0.40Keytruda Qlex +0.30

2026-10-29 10:51:29 UTC#536370duplicateconfirmednews

Merck Q3 sales rise 5% to $18.1B; FY 2026 guidance raised despite $400M one-time charge

quartrimportance 0.40trust 0.70Merck & Co., Inc. +0.50Keytruda +0.40Winrevair +0.40+1 entities

2026-10-29 10:49:37 UTC#536362duplicateconfirmednews

Merck Q3 earnings beat estimates and 2026 outlook raised

seeking alphaimportance 0.30trust 0.70Merck & Co., Inc. +0.60

2026-10-29 10:45:29 UTC#536267duplicateconfirmednews

Merck Q3 sales rise 5% to $18.1B on oncology strength; FY26 guidance raised despite lower quarterly EPS

quartrimportance 0.30trust 0.70Merck & Co., Inc. +0.40WINREVAIR +0.50

2026-10-29 10:41:00 UTC#536266duplicateconfirmednews

Merck Q3 revenue grows on Keytruda and Winrevair sales

wsjimportance 0.30trust 0.90Merck & Co., Inc. +0.40Keytruda +0.50Winrevair +0.50

2026-10-29 10:35:35 UTC#536191updateconfirmeddata release

Merck Q3 2026: Sales $18.09B vs $17.31B est, Adj EPS $2.49 vs $2.07 est; Keytruda and Gardasil revenue beat

first_squawkimportance 0.80trust 0.80Merck & Co., Inc. +0.60Keytruda +0.60Gardasil +0.50

2026-10-29 10:31:55 UTC#536144newconfirmednews

Merck & Co. reports Q3 2026 earnings

financial_juiceimportance 0.40trust 0.60Merck & Co., Inc. 0

2026-10-29 10:31:47 UTC#536206duplicateconfirmednews

Merck Q3 2026 Non-GAAP EPS $2.49 beats by $0.40, Revenue $18.09B beats by $760M

seeking alphaimportance 0.40trust 0.80Merck & Co., Inc. +0.60

2026-10-29 10:31:13 UTC#536200duplicateconfirmednews

Merck beats Q3 estimates and raises full-year profit outlook on strong Keytruda sales

cnbcimportance 0.30trust 0.80Merck & Co., Inc. +0.60Keytruda +0.60

2026-10-28 23:11:00 UTC#533291duplicateconfirmednews

Genmab shares rise 28% following positive Phase 3 trial results for petosemtamab in head and neck cancer, WSJ reports

dow_jonesimportance 0.30trust 0.90Genmab A/S +0.80Merck & Co., Inc. +0.30Pembrolizumab +0.30+2 entities

2026-10-28 15:55:01 UTC#530293newconfirmednews

Merck and Eli Lilly earnings previews: Market focus on upcoming quarterly results

seeking alphaimportance 0.40trust 0.70Merck & Co., Inc. 0Eli Lilly and Company 0

2026-10-28 14:10:00 UTC#529593updateconfirmednews

Genmab reports petosemtamab plus Keytruda reduces death risk by 50% in Phase 3 head and neck cancer trial

seeking alphaimportance 0.60trust 0.70Genmab A/S +0.70Merck & Co., Inc. +0.60Pembrolizumab +0.60

2026-10-27 20:30:47 UTC#524068newconfirmedpress release

Mercer International to report Q3 2026 results on November 5, 2026

financial postimportance 0.30trust 1.00Mercer International Inc. 0Juan Carlos Bueno 0Richard Short 0

2026-10-27 19:05:00 UTC#523509newconfirmednews

CIBC downgrades Mercer International to Underperformer from Neutral, cuts price target to $0.15 from $0.75

dow_jonesimportance 0.40trust 0.70Mercer International Inc. -0.80Canadian Imperial Bank of Commerce -0.20